Pfizer on COVID-19 antiviral tablet will already have a competition in the US. Monga Associated Press reports, Food and Drug Administration has provided emergency services permission for Merck’s Molnupiravir tablets. The treatment reduces the recurrence of SARS-CoV-2 by placing “defects” in the genetic predisposition while the disease is still young, which in turn reduces the risk of minor or minor complications in high-risk patients.
The drug cannot be used as Pfizer’s Paxlovid, however. Merck donations may be available for 18 years or older compared to Pfizer’s 12 years, as there are concerns that could affect bone growth and cartilage in young patients. There are also warnings against using it during pregnancy or trying to get pregnant – the FDA said people should use contraceptives during and after treatment, with women waiting three days and men waiting three months.
Molnupiravir also does not look as effective as Paxlovid. While Pfizer’s response reduced hospitalization and mortality by 90 percent, Merck achieved only 30 percent. Pills can be second, especially if Paxlovid is not available. The products of both companies are expected to remain active against the Omicron virus because they do not look for mutant proteins.
However, this could be another tool to help reduce COVID-19 levels and deaths. Pfizer pill will be readily available when the US calls for enough to treat 10 million patients, but Merck’s medication will be enough to cover 3.1 million. Even a small amount of energy can save thousands of lives from deadly diseases.
All sales supported by Engadget are selected by our writing team, independent of our parent company. Some of our articles include links to links. When you purchase something through one of these links, we may be able to find a partner.
Source link
